Boundless Bio, Inc. Share Price & Technical Analysis
BOLD · $1.48 (+2.78%)
Healthcare / Biotechnology
$1.48
+2.78%
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negati…
Price chart
Seasonality
May has 0 positive and 3 negative years (last 3 years shown)
-7% return in May, -23% avg return in past 3 year May month.
30% return in 2026, -90% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 0% | 0% | 0% | 36% | -7% | – | – | – | – | – | – | – | 30% |
| 25 | -21% | -14% | -21% | 20% | -39% | -9% | 20% | -8% | 9% | 17% | -14% | 0% | -60% |
| 24 | – | – | 0% | -32% | -7% | -56% | 0% | -5% | -3% | -17% | -7% | 7% | -120% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Strong · Uptrend
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$33.13M
P/E ratio
—
52W high
$1.68
52W low
$0.96
Volume
72,400
Beta
0.95
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Boundless Bio, Inc. share price today?
- Boundless Bio, Inc. (BOLD) last traded around $1.48 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does BOLD have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for BOLD. Download the app for real-time alerts.
- How can I analyze Boundless Bio, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.